Morgans has tipped GXL to disappoint with its FY results. I don't know the reasoning, but some of the recent selling could be their clients getting out.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025